Recent Updates
Recently added Catalysts
TNGX Positive Sentiment

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Wednesday, November 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Tango Therapeutics, Inc. announced that Dr. Adam Crystal will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3. The event will be accessible via a live webcast, which will also be archived for 90 days. This participation highlights Tango's focus on advancing cancer therapies.
Price reaction · baseline $10.57 (2025-11-25 close) · hit pre-market · clean, no other TNGX news in the window
day 0 close · peak
+1.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant healthcare conference
  • Opportunity for visibility and engagement with investors
  • Showcases commitment to advancing cancer treatment

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
1%
average across 2 past catalysts
Cash runway
~78 mo
Minimal dilution risk
Lead asset
Perindopril-indapamide
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37thAnnual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:

Frequently Asked Questions

When is Tango Therapeutics participating in the conference?

Tango Therapeutics will participate on December 3 at 1:30pm ET.

Who will represent Tango Therapeutics at the event?

Dr. Adam Crystal, President of Research & Development, will represent the company.

How can I access the conference webcast?

The live webcast will be available on the company's Investors page.

Will the webcast be available after the event?

Yes, a replay will be archived for 90 days following the presentation.

ShareAdd on Google
Tags: TNGX Viatris Investor Conferences Healthcare Tango Therapeutics Piper Sandler healthcare conference cancer treatment
Last updated: Nov 26, 2025

Biotech snapshot

Cash runway
$1014M liquidity · $13M/mo burn
~78 mo
Minimal dilution risk
Lead asset
Perindopril-indapamidePhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+24%
best trade around TNGX's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TNGX.

See every catalyst's timing & PoA →